Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

1. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-72.10.1200/JCO.2005.04.8306Search in Google Scholar

2. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.Search in Google Scholar

3. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012; 18: 2278-89.10.1158/1078-0432.CCR-11-1593Search in Google Scholar

4. Schmitz S, Machiels JP. Molecular biology of squamous cell carcinoma of the head and neck : relevance and therapeutic implications. Expert Rev Anticancer Ther 2010; 10: 1471-84.10.1586/era.10.115Search in Google Scholar

5. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.10.1056/NEJMoa053422Search in Google Scholar

6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.10.1016/S1470-2045(09)70311-0Search in Google Scholar

7. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.10.1056/NEJMoa080265618784101Search in Google Scholar

8. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7.10.1200/JCO.2006.06.744717538161Search in Google Scholar

9. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.Cancer Cell 2005; 7: 301-11.10.1016/j.ccr.2005.03.00315837620Search in Google Scholar

10. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009; 58: 1853-64.10.1007/s00262-009-0697-4342628919319529Search in Google Scholar

11. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.Search in Google Scholar

12. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007; 13: 6555-60.10.1158/1078-0432.CCR-07-161018006754Search in Google Scholar

13. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559-67.10.1002/jcp.2126017894407Search in Google Scholar

14. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-101.Search in Google Scholar

15. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009; 4: e6539.10.1371/journal.pone.0006539271652919657384Search in Google Scholar

16. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69: 6347-54.10.1158/0008-5472.CAN-09-0657282504619622766Search in Google Scholar

17. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76: S36-42.10.1259/bjr/1848664215456712Search in Google Scholar

18. Veit-Haibach P, Schmid D, Strobel K, Soyka JD, Schaefer NG, Haerle SK, et al. Combined PET/CT-perfusion in patients with head and neck cancers. Eur Radiol 2013; 23: 163-73.10.1007/s00330-012-2564-522772151Search in Google Scholar

19. Rumboldt Z, Al-Okaili R, Deveikis JP. Perfusion CT for head and neck tumors: pilot study. Am J Neuroradiol 2005; 26: 1178-85.Search in Google Scholar

20. Gandhi D, Chepeha DB, Miller T, Carlos RC, Bradford CR, Karamchandani R, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ -preservation therapy. Am J Neuroradiol 2006; 27: 101-6.Search in Google Scholar

21. Zima A, Carlos R, Gandhi D, Case I, Teknos T, Mukherji SK. Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? Am J Neuroradiol 2007; 28: 328-34.Search in Google Scholar

22. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007; 55: 79-87.10.1016/j.lungcan.2006.08.01817046099Search in Google Scholar

23. Hirasawa S, Tsushima Y, Takei H, Hirasawa H, Taketomi-Takahashi A, Takano A, et al. Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol 2007; 14: 312-8.10.1016/j.acra.2006.12.01717307664Search in Google Scholar

24. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002; 26: 185-90.10.1097/00004728-200203000-0000411884771Search in Google Scholar

25. Halligan S. Reproducibility, repeatability, correlation and measurement error. Br J Radiol 2002; 75: 193-5.10.1259/bjr.75.890.75019311893647Search in Google Scholar

26. Ash L, Teknos TN, Gandhi D, Patel S, Mukherji SK. Head and neck squamous cell carcinoma: CT perfusion can help noninvasively predict intratumoral microvessel density. Radiology 2009; 251: 422-8.10.1148/radiol.251208074319276321Search in Google Scholar

27. Surlan-Popovic K, Bisdas S, Rumboldt Z, Koh TS, Strojan P. Changes in perfusion CT of advanced squamous cell carcinoma of the head and neck treated during the course of concomitant chemoradiotherapy. Am J Neuroradiol 2010; 31: 570-5.10.3174/ajnr.A1859Search in Google Scholar

28. Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol 2005; 26: 777-83.Search in Google Scholar

29. Kosaka N, Uematsu H, Kimura H, Ishimori Y, Kurokawa T, Matsuda T, et al. Assessment of the vascularity of uterine leiomyomas using double-echo dynamic perfusion-weighted MRI with the first-pass pharmacokinetic model: correlation with histopathology. Invest Radiol 2007; 42: 629-35.10.1097/RLI.0b013e318059ae69Search in Google Scholar

30. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-6.10.1016/S0360-3016(03)00764-8Search in Google Scholar

31. Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, Lhommel R, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013; 24: 2261-6.10.1093/annonc/mdt180Search in Google Scholar

32. Abramyuk A, Wolf G, Shakirin G, Haberland U, Tokalov S, Koch A, et al. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors. Acta Radiol 2010; 51: 793-9.10.3109/02841851.2010.491092Search in Google Scholar

33. Donaldson SB, West CM, Davidson SE, Carrington BM, Hutchison G, Jones AP, et al. A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix. Magn Reson Med 2010; 63: 691-700.10.1002/mrm.22217Search in Google Scholar

34. Coleman TF, Li Y. An interior, trust region approach for nonlinear minimization subject to bounds. SIAM J Optim 1996; 6: 418-45.10.1137/0806023Search in Google Scholar

35. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82.10.1016/S0959-8049(99)00229-4Search in Google Scholar

36. Thévenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 1998; 7: 27-41.10.1109/83.65084818267377Search in Google Scholar

37. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z et al. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxiainducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005; 24: 4433-41.10.1038/sj.onc.120862515806152Search in Google Scholar

38. Jouan-Hureaux V, Boura C, Merlin JL, Faivre B. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab. Microvasc Res 2012; 83: 131-7.10.1016/j.mvr.2011.07.00821820450Search in Google Scholar

39. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, et al. Stressrelated mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2009; 9: 4514-21.Search in Google Scholar

40. Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G 2nd, Camp ER, et al. Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther 2008; 7: 3064-70. 10.1158/1535-7163.MCT-08-0615258183318790786Search in Google Scholar